Equities

Lyka Labs Ltd

LYKALABS:NSI

Lyka Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)149.02
  • Today's Change2.02 / 1.37%
  • Shares traded100.27k
  • 1 Year change+34.25%
  • Beta1.4076
Data delayed at least 15 minutes, as of Sep 20 2024 11:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Lyka Labs Ltd has grown net income from a loss of -132.12m to a smaller loss of -24.89m primarily through revenue growth (930.73m to 1.11bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the 19.47% growth in revenues contributed enough to still see net income improve.
Gross margin60.45%
Net profit margin0.51%
Operating margin4.45%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, cash reserves at Lyka Labs Ltd fell by 57.62m. Cash Flow from Financing totalled 19.53m or 1.76% of revenues. In addition the company generated 17.73m in cash from operations while cash used for investing totalled 94.88m.
Cash flow per share3.52
Price/Cash flow per share45.00
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Lyka Labs Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.